By Jennifer Langley
Histogenics Corp (NASDAQ:HSGX) has received an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company.
Analysts have set a 1-year consensus price objective of $17.00 for the company and are predicting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Histogenics Corp an industry rank of 102 out of 265 based on the ratings given to related companies.
Histogenics Corp (NASDAQ:HSGX) traded up 2.32% during mid-day trading on Monday, reaching $4.07. The company had a trading volume of 140 shares. The stock’s market capitalization is $53.84 million. Histogenics Corp has a 52 week low of $3.78 and a 52 week high of $12.47. The stock has a 50 day moving average of $5.62 and a 200 day moving average of $7.19.